Analysis of influenza viruses from patients clinically suspected of infection with an oseltamivir resistant virus during the 2009 pandemic in the United States

被引:40
作者
Nguyen, Ha T. [1 ,3 ,4 ]
Trujillo, Alma A. [1 ]
Sheu, Tiffany G. [1 ,4 ]
Levine, Marnie [1 ,4 ]
Mishin, Vasiliy P. [1 ]
Shaw, Michael [1 ]
Ades, Edwin W. [2 ]
Klimov, Alexander I. [1 ]
Fry, Alicia M. [1 ]
Gubareva, Larisa V. [1 ]
机构
[1] Ctr Dis Control & Prevent, Influenza Div, Atlanta, GA 30333 USA
[2] Ctr Dis Control & Prevent, Div Bacterial Dis, Atlanta, GA USA
[3] Atlanta Res & Educ Fdn, Atlanta, GA USA
[4] Battelle Mem Inst, Atlanta, GA USA
关键词
Pandemic H1N1; Neuraminidase inhibitor; Pyrosequencing; Neuraminidase inhibition assay; H275Y; I223K; I223R; IMMUNOCOMPROMISED PATIENTS; DRUG-RESISTANCE; H1N1; SUSCEPTIBILITY; MUTATION; SEASON;
D O I
10.1016/j.antiviral.2012.01.006
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
During the 2009 influenza pandemic, the Centers for Disease Control and Prevention provided antiviral susceptibility testing for patients infected with suspected drug-resistant viruses. Specimens from 72 patients admitted to an intensive care unit or with a severe immunocompromising condition, who failed to clinically improve after oseltamivir treatment, were accepted for testing. Respiratory specimens were tested for the presence of the oseltamivir resistance-conferring H275Y substitution in the neuraminidase (NA) by pyrosequencing. Virus isolates propagated in MDCK cells were tested in phenotypic NA inhibition (NI) assays using licensed NA inhibitors (NAIs), zanamivir and oseltamivir, and investigational NAIs, peramivir and laninamivir. Conventional sequencing and plaque purification were conducted on a subset of viruses. Pyrosequencing data were obtained for 87 specimens collected from 58 of the 72(81%) patients. Of all patients, 27 (38%) had at least one specimen in which H275Y was detected. Analysis of sequential samples from nine patients revealed intra-treatment emergence of H275Y variant and a shift from wild-type-to-H275Y in quasispecies during oseltamivir therapy. A shift in the H275Y proportion was observed as a result of virus propagation in MDCK cells. Overall, the NI method was less sensitive than pyrosequencing in detecting the presence of H275Y variants in virus isolates. Using the NI method, isolates containing H275Y variant at >= 50% exhibited resistance to oseltamivir and peramivir, but retained full susceptibility to zanamivir. H275Y viruses recovered from two patients had an additional substitution I223K or I223R that conferred a 38-52- and 33-97-fold enhancement in oseltamivir- and peramivir-resistance, respectively. These viruses also showed decreased susceptibility to zanamivir and laninamivir. These data suggest that pyrosequencing is a powerful tool for timely detection of NAI resistant viruses and that NI assays are needed for comprehensive testing to detect novel resistance substitutions. (C) 2012 Elsevier B.V. All rights reserved.
引用
收藏
页码:381 / 386
页数:6
相关论文
共 21 条
  • [1] Bautista E, 2010, NEW ENGL J MED, V362, P1708, DOI 10.1056/NEJMra1000449
  • [2] Cluster of Oseltamivir-Resistant 2009 Pandemic Influenza A (H1N1) Virus Infections on a Hospital Ward among Immunocompromised Patients-North Carolina, 2009
    Chen, Luke F.
    Dailey, Natalie J. M.
    Rao, Agam K.
    Fleischauer, Aaron T.
    Greenwald, Ian
    Deyde, Varough M.
    Moore, Zack S.
    Anderson, Deverick J.
    Duffy, Jonathan
    Gubareva, Larisa V.
    Sexton, Daniel J.
    Fry, Alicia M.
    Srinivasan, Arjun
    Wolfe, Cameron R.
    [J]. JOURNAL OF INFECTIOUS DISEASES, 2011, 203 (06) : 838 - 846
  • [3] Detection of Molecular Markers of Drug Resistance in 2009 Pandemic Influenza A (H1N1) Viruses by Pyrosequencing
    Deyde, Varough M.
    Sheu, Tiffany G.
    Trujillo, A. Angelica
    Okomo-Adhiambo, Margaret
    Garten, Rebecca
    Klimov, Alexander I.
    Gubareva, Larisa V.
    [J]. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2010, 54 (03) : 1102 - 1110
  • [4] Infections With Oseltamivir-Resistant Influenza A(H1N1) Virus in the United States
    Dharan, Nila J.
    Gubareva, Larisa V.
    Meyer, John J.
    Okomo-Adhiambo, Margaret
    McClinton, Reginald C.
    Marshall, Steven A.
    George, Kirsten St.
    Epperson, Scott
    Brammer, Lynnette
    Klimov, Alexander I.
    Bresee, Joseph S.
    Fry, Alicia M.
    [J]. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2009, 301 (10): : 1034 - 1041
  • [5] Characteristics of Patients with Oseltamivir-Resistant Pandemic (H1N1) 2009, United States
    Graitcer, Samuel B.
    Gubareva, Larisa
    Kamimoto, Laurie
    Doshi, Saumil
    Vandermeer, Meredith
    Louie, Janice
    Waters, Christine
    Moore, Zack
    Sleeman, Katrina
    Okomo-Adhiambo, Margaret
    Marshall, Steven A.
    George, Kirsten St.
    Pan, Chao-Yang
    LaPlante, Jennifer M.
    Klimov, Alexander
    Fry, Alicia M.
    [J]. EMERGING INFECTIOUS DISEASES, 2011, 17 (02) : 255 - 257
  • [6] Comprehensive assessment of 2009 pandemic influenza A (H1N1) virus drug susceptibility in vitro
    Gubareva, Larisa V.
    Trujillo, A. Angelica
    Okomo-Adhiambo, Margaret
    Mishin, Vasiliy P.
    Deyde, Varough M.
    Sleeman, Katrina
    Nguyen, Ha T.
    Sheu, Tiffany G.
    Garten, Rebecca J.
    Shaw, Michael W.
    Fry, Alicia M.
    Klimov, Alexander I.
    [J]. ANTIVIRAL THERAPY, 2010, 15 (08) : 1151 - 1159
  • [7] Harvala H, 2010, EUROSURVEILLANCE, V15, P2
  • [9] Kniss Krista, 2011, Morbidity and Mortality Weekly Report, V60, P705
  • [10] Lackenby A, 2008, ANTIVIR THER, V13, P809